Research insight: Peptide purity, peptide content and residual-solvent levels are different analytical measurements. A credible COA should not blur them together.

Why residual solvents deserve their own test

A peptide may show a dominant peak in an HPLC chromatogram yet still contain non-peptide material. Organic solvents used during synthesis and purification can remain after isolation and drying. They are chemically different from peptide-related impurities, and the usual HPLC purity percentage does not establish their concentration. This distinction matters for laboratories comparing lots, preparing accurately characterised reference materials, or interpreting a certificate of analysis (COA).

Where solvents enter peptide manufacturing

Solid-phase peptide synthesis (SPPS) uses solvents to swell resin, dissolve reagents, wash intermediates and enable coupling or deprotection. N,N-dimethylformamide (DMF) and N-methyl-2-pyrrolidone (NMP) are familiar examples; dichloromethane may appear in particular workflows. Preparative reversed-phase chromatography commonly uses acetonitrile-containing mobile phases. The actual solvent profile depends on the manufacturer’s process: it is inappropriate to assume every peptide has encountered every solvent. Subsequent washing, solvent exchange and drying aim to reduce residues, but a process description alone is not a measured result.

HPLC peak-area purity is not total composition

An HPLC result such as 98% commonly refers to the proportion of integrated detector response attributed to the main peak under a defined method. It is not automatically 98% of the powder mass, and different compounds can have different detector responses. Residual solvents, water and counterions may contribute to the vial’s mass without appearing as peptide-related peaks in that assay. Conversely, an assay specifically validated for peptide content addresses a different question from chromatographic peak-area purity. For a broader explanation, see our guide to peptide reference standards and calibration.

What ICH Q3C(R9) actually says

The International Council for Harmonisation’s Q3C(R9) guideline provides a risk-based framework for residual solvents in pharmaceuticals. It groups solvents into Class 1 (generally to be avoided), Class 2 (to be limited) and Class 3 (lower toxic potential). Its limits relate to pharmaceutical exposure and are not automatic legal specifications for every research-use-only laboratory reagent. Q3C(R9) became effective in the EU on 29 April 2024. The EMA also consulted on draft annex changes between 29 April and 30 June 2026; a consultation is not the same as an adopted new requirement. Researchers can use the framework to understand relative solvent concern while still defining specifications appropriate to their intended analytical use.

Why the identity of the solvent matters

Reporting only “residual solvents: pass” can obscure important details. The solvent name, result, unit, method, reporting threshold and specification should ideally be clear. A result of 100 ppm means approximately 100 milligrams of the named substance per kilogram of tested material, not 100 ppm of total unidentified impurities. A non-detect result means the analyte was not detected under that method’s conditions; it does not mean an absolute absence. Limits of detection and quantification determine how informative the result is.

How laboratories measure solvent residues

Headspace gas chromatography (HS-GC), frequently with flame-ionisation detection, is a common technique. A sealed sample vial is equilibrated so volatile compounds partition into the gas above the sample; a portion of that gas is analysed. Some methods use GC-MS for additional identification. Crucially, a method must be suitable for the solvent and sample matrix. Less volatile, strongly retained or poorly partitioning compounds can require careful sample preparation and validation. A generic test panel cannot rule out a solvent it was never designed to measure. Q3C(R9) explicitly emphasises considering volatility when validating the analytical procedure.

A useful example: two different COAs

Imagine two hypothetical peptide batches. Batch A reports HPLC main-peak area purity of 99.1% and no residual-solvent results. Batch B reports HPLC main-peak area purity of 98.7%, plus a validated GC panel showing identified solvents below its stated reporting thresholds. Batch A has the higher reported HPLC percentage, but it does not follow that Batch A has lower residual solvents or better total compositional characterisation. Equally, Batch B’s results do not prove sterility, identity or suitability for any biological use. The example illustrates how separate analytical measurements answer separate questions; it is not a comparison of actual 24hour Peptides stock.

Residual solvent testing versus other quality checks

LC-MS can support molecular-mass or sequence-related identity assessments; peptide HPLC can help characterise chromatographic purity; water determination can quantify moisture; counterion analysis can characterise associated ions; and a targeted solvent method measures specified organic residues. None is a universal substitute for the others. The interpretation also depends on whether a result refers to the same batch, whether the method was validated for that matrix, and whether the laboratory supplies a complete report rather than a cropped screenshot. Read our COA interpretation guide and TFA versus acetate discussion for related distinctions.

Questions to ask when reviewing a research COA

First, does the report identify the exact batch and tested sample? Second, which solvents were targeted, and why were they selected? Third, are values expressed in ppm or another clear unit? Fourth, are the detection or quantification limits stated for non-detect results? Fifth, is the method suitable for the relevant solvents and matrix? Sixth, is the report from the named laboratory, with a date and traceable reference? Finally, is the conclusion narrowly worded to match what was measured? A solvent panel should never be presented as proof of overall product safety.

What research laboratories should take away

Residual-solvent analysis is a separate piece of the analytical-quality picture. A high peptide HPLC percentage is useful within the scope of its method, but cannot replace a targeted assessment of manufacturing solvent residues. The most defensible interpretation combines process knowledge, batch-specific analytical evidence and transparent reporting of limitations. For the wider research framework, visit our Research Peptides UK Complete Guide and the COA Library.

Scientific sources and further reading

1. EMA: ICH Q3C(R9), residual solvents (effective 29 April 2024).
2. ICH Q3C(R9), full guideline, including analytical procedures and scope.
3. Sustainability Challenges in Peptide Synthesis and Purification: From R&D to Production, Journal of Organic Chemistry.
4. Challenges and Achievements of Peptide Synthesis in Aqueous and Micellar Media, ChemBioChem (2025).